Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Rhea-AI Summary

Beyond Air (NASDAQ: XAIR) will release second fiscal quarter 2026 financial results for the period ended September 30, 2025 on Monday, November 10, 2025. The company's management will host a conference call and webcast the same day at 4:30 PM Eastern Time to discuss results.

Dial-in details: Domestic 1-877-407-0784, International 1-201-689-8560, Conference ID 13756730. A live webcast will be available in the Events section of the company's website, and an online replay will be posted about one hour after the call.

GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Conference Call & Webcast
Monday, November 10th @ 4:30 PM ET
Domestic:	1-877-407-0784
International:	1-201-689-8560
Conference ID:	13756730
Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.

About Beyond Air^®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit^® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577

FAQ

When will Beyond Air (XAIR) report Q2 fiscal 2026 results?

Beyond Air will report results for the quarter ended September 30, 2025 on November 10, 2025.

What time is the Beyond Air (XAIR) Q2 2026 earnings call on November 10, 2025?

The conference call and webcast begin at 4:30 PM Eastern Time on November 10, 2025.

How can investors join the Beyond Air (XAIR) November 10, 2025 call?

Dial Domestic 1-877-407-0784 or International 1-201-689-8560 and use Conference ID 13756730, or join the live webcast on the company's Events page.

When and where will the replay of the Beyond Air (XAIR) Q2 2026 webcast be available?

An online replay will be posted on the company's website about one hour after the call.

Will Beyond Air (XAIR) provide presentation materials for the November 10, 2025 webcast?

Presentation materials, if provided, will be accessible in the Events section of the company's investor website alongside the webcast and replay.